BAFNAPH / NSE / Biotechnology & Drugs
Bafna Pharmaceuticals
1Y Price Trend
Key Information
Recommendations
Target High204.95
Target Low72.25
Target Mean0
Target Median0
Risk Metrics
Overall RiskHigh risk
Board Risk55.09
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent Markets Mojo
Above All Moving Averages and Now at Upper Circuit: Bafna Pharmaceuticals Ltd Gains 5.0% in a Single Session Markets Mojo
Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges Markets Mojo
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent Markets Mojo
Bafna Pharmaceuticals FY26 net profit rises to ₹1,109.98 lakh scanx.trade
Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.09% Gain — Buyers Queue, Sellers Absent Markets Mojo
Bafna Pharmaceuticals standalone net profit rises 109.92% in the March 2026 quarter Business Standard
BAFNAPH: FY26 net profit more than doubled year-over-year, with strong revenue growth and clean audit TradingView
© SharekeyX | Rusaka Technologies 2024-2026